# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
<tr>
<td>Pathology:</td>
<td>Stage:</td>
</tr>
</tbody>
</table>

**Line of Therapy:**
- Neoadjuvant/Pre-Op
- Adjuvant/Post-Op
  - 1st Line
  - 2nd Line
  - 3rd Line
  - 3rd Line+ 
  - Maintenance

**Biomarkers/Characteristics:** (Select all that apply)
- BRAF: __V600E Mutation ___ V600K Mutation ___Wild type ___Not reported
- EGFR: ___Mutation ___Wild type ___Not reported
- T790M mutation: ___Positive ___Negative ___Not reported
- MET amplification: ___Positive ___Negative ___Not reported
- ALK: ___Positive ___Negative ___Not reported
- PD-L1 expression: ___1% to 49% ___ >50% ___Negative ___Not reported
- RET gene rearrangement: ___Absent ___Present ___Not reported
- Microsatellite instability: ___dMMR/MSI-H ___MSI-L ___Not reported
- ROS1 rearrangement: ___Positive ___Negative ___Not reported

### Neoadjuvant/Preoperative/Induction Therapy or Adjuvant/Definitive Therapy

**Adjuvant Therapy**
- Carboplatin and paclitaxel
- Carboplatin and gemcitabine (Gemzar)
- Carboplatin and vinorelbine (Navelbine)

**Metastatic Disease | Squamous | ALK/EGFR Negative (ROS Negative or Unknown) | TPS > 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2**
- Pembrolizumab (Keytruda)*

**Metastatic Disease | Squamous | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2**
- Pembrolizumab (Keytruda)*, carboplatin, and paclitaxel

**Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS > 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2**
- Pembrolizumab (Keytruda)*

**Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2**
- Carboplatin†, pemetrexed (Alimta), and pembrolizumab (Keytruda)

**Metastatic Disease | Squamous or Nonsquamous | Immunotherapy-Ineligible | First Line of Therapy (1st Line) | ECOG PS: 0-2**
- Carboplatin and paclitaxel
- Carboplatin, paclitaxel, and bevacizumab (NON-SQUAMOUS ONLY)
- Carboplatin† and gemcitabine (Gemzar)
- Carboplatin† and pemetrexed (Alimta) (NON-SQUAMOUS ONLY)

* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate
† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.
‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.
Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways (continued)

**Metastatic Disease | Non-Squamous | Maintenance | ECOG PS: 0-2**

___Continuation bevacizumab
___Continuation pemetrexed (Alimta)
___Pembrolizumab (Keytruda)* and pemetrexed (Alimta) (if previously treated with carboplatin†, pemetrexed, and pembrolizumab)
___Switch pemetrexed (Alimta)

**Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2**

___Atezolizumab (Tecentriq) (if no prior checkpoint inhibitors)
___Nivolumab (Opdivo) (if no prior checkpoint inhibitors)
___Carboplatin† and paclitaxel‡
___Carboplatin† and gemcitabine (Gemzar)‡
___Carboplatin† and pemetrexed (Alimta)‡

**Metastatic Disease | ALK Positive | First Line of Therapy (1st Line)**

___Alectinib (Alecensa)

**Metastatic Disease | EGFR Positive | First Line of Therapy (1st Line)**

___Osimertinib (Tagrisso)

**Metastatic Disease | ALK or EGFR Positive | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2**

___Carboplatin† and paclitaxel
___Cisplatin† and gemcitabine (Gemzar)
___Cisplatin† and pemetrexed (Alimta)

**Metastatic Disease | EGFR Positive | ECOG PS: 3-4**

___Erlotinib (Tarceva)

* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

---

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.